Back to Archived News
NanoBio Awarded Key Patent Covering Vaccine and Anti-Infective Product Platforms
Tuesday, February 02, 2010
Ann Arbor, MI -- NanoBio Corporation announced today that a sixth U.S. patent covering its novel nanoemulsion technology has been awarded. The patent encompasses composition of matter claims for the company’s lead anti-infective and vaccine product candidates.
"We are very pleased with this patent award in that the new claims circumscribe all of NanoBio’s anti-infective and dermatological products, as well as our intranasal and intramuscular vaccine adjuvants," said James R. Baker, Jr., MD, NanoBio’s CEO and founder. "The timing of this allowance coincides nicely with several very important development milestones at NanoBio."
In December 2009, NanoBio and GlaxoSmithKline plc (GSK) announced an exclusive licensing agreement in the United States and Canada for the over-the-counter use of NB-001, NanoBio’s lead product for the treatment of herpes labialis (cold sores). NanoBio is currently preparing to study the efficacy and safety of 0.3% NB-001 in two Phase 3 trials.
In addition, NanoBio’s lead vaccine candidate, NB-1008, a seasonal influenza vaccine administered via a nasal dropper, has shown very promising results in a recently completed Phase 1 clinical study. The company is currently in partnership discussions with several parties regarding NB-1008.
The development of the nanoemulsion platform began in the 1990s at the University of Michigan, and has since been supported by over $110 million in grants, investments and partnership funding. The newly issued patent (U.S. #7,655,252) is licensed from the University of Michigan to NanoBio Corp. on an exclusive, worldwide basis. With this new patent, NanoBio now holds six U.S. patents and has filed over 30 additional applications.
About NanoBio
NanoBio® Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat™ technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company’s headquarters and laboratory facilities are located in Ann Arbor, Michigan.
Back to Archived News
